ES2150663T3 - Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina. - Google Patents

Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.

Info

Publication number
ES2150663T3
ES2150663T3 ES96906202T ES96906202T ES2150663T3 ES 2150663 T3 ES2150663 T3 ES 2150663T3 ES 96906202 T ES96906202 T ES 96906202T ES 96906202 T ES96906202 T ES 96906202T ES 2150663 T3 ES2150663 T3 ES 2150663T3
Authority
ES
Spain
Prior art keywords
desethylloxibutinine
oxybutinine
urinary incontinence
treatment
refers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96906202T
Other languages
English (en)
Spanish (es)
Inventor
Gunnar Aberg
Cullough John R Mc
Yue Fang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,542 external-priority patent/US5532278A/en
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of ES2150663T3 publication Critical patent/ES2150663T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES96906202T 1995-01-31 1996-01-25 Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina. Expired - Lifetime ES2150663T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/381,542 US5532278A (en) 1995-01-31 1995-01-31 Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US08/480,194 US5677346A (en) 1995-01-31 1995-06-07 Treating urinary incontinence using (S)-desethyloxybutynin

Publications (1)

Publication Number Publication Date
ES2150663T3 true ES2150663T3 (es) 2000-12-01

Family

ID=27009434

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96906202T Expired - Lifetime ES2150663T3 (es) 1995-01-31 1996-01-25 Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.

Country Status (25)

Country Link
US (1) US5677346A (da)
EP (1) EP0806948B1 (da)
JP (1) JPH11511730A (da)
KR (1) KR100390271B1 (da)
CN (1) CN1151786C (da)
AT (1) ATE196252T1 (da)
AU (1) AU706741B2 (da)
BR (1) BR9607001A (da)
CA (1) CA2211400C (da)
CZ (1) CZ290093B6 (da)
DE (1) DE69610290T2 (da)
DK (1) DK0806948T3 (da)
ES (1) ES2150663T3 (da)
FI (1) FI973163A (da)
GR (1) GR3034974T3 (da)
HK (1) HK1017986A1 (da)
HU (1) HUP9800794A3 (da)
NO (1) NO315927B1 (da)
NZ (1) NZ303372A (da)
PL (1) PL182768B1 (da)
PT (1) PT806948E (da)
RU (1) RU2181589C2 (da)
SK (1) SK283313B6 (da)
UA (1) UA45387C2 (da)
WO (1) WO1996023492A1 (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039519A2 (es) * 2001-11-06 2003-05-15 Osmotica Corp. Forma de dosificación de liberación controlada dual

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US6171298B1 (en) 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법
US6123961A (en) * 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
JP2001527039A (ja) * 1997-12-31 2001-12-25 セプラコール， インク． 尿失禁を治療するためのｓ−プロサイクリディン
US6183461B1 (en) 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
US6013830A (en) * 1998-03-30 2000-01-11 Sepracor Inc. Asymmetric grignard synthesis with cyclic 1,2 aminoalcohols
EA002720B1 (ru) * 1998-08-27 2002-08-29 Фармациа Энд Апджон Аб Терапевтическая композиция для введения толтеродина с контролируемым высвобождением и способ лечения мочевого пузыря с её использованием
WO2000071108A2 (en) * 1999-05-20 2000-11-30 Sepracor Inc. Methods for treatment of asthma using s-oxybutynin
US6432446B2 (en) * 2000-02-03 2002-08-13 Bridge Pharma, Inc. Non-arrhythmogenic metabolite of oxybutynin
US6521724B2 (en) 2000-03-10 2003-02-18 E. I. Du Pont De Nemours And Company Polymerization process
US6436428B1 (en) 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
AU2001253782B2 (en) * 2000-04-26 2006-06-29 Allergan Sales, Llc Minimizing adverse experience associated with oxybutynin therapy
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
EP1286591B1 (en) * 2000-06-07 2010-10-06 Watson Pharmaceuticals, Inc. Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin
AU2001282064B2 (en) * 2000-08-03 2007-02-01 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
DE10103262A1 (de) * 2001-01-25 2002-08-01 Axel Schmidt-Dossi Arzneimittel gegen Blasenfunktionsstörung
ATE447970T1 (de) 2001-02-08 2009-11-15 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
JP4959907B2 (ja) * 2001-03-27 2012-06-27 ワーナー チルコット（アイルランド）リミティド 抗菌剤投与のための膣内用ドラッグデリバリーデバイス
US20030027856A1 (en) * 2001-06-29 2003-02-06 Aberg A.K. Gunnar Tolterodine metabolites
CA2464217A1 (en) * 2001-11-05 2003-05-15 Pharmacia & Upjohn Company Antimuscarinic aerosol
US7921999B1 (en) 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
AU2002241721A1 (en) * 2001-12-21 2003-09-02 Bridge Pharma, Inc. A non-arrhythmogenic metabolite of oxybutynin
ATE295726T1 (de) * 2002-12-02 2005-06-15 Sanol Arznei Schwarz Gmbh Verabreichung von rotigotine zur behandlung der parkinson'schen krankheit durch iontophorese
JP5619337B2 (ja) 2003-10-10 2014-11-05 フェリング ビー．ブイ． 皮膚残渣を最小限に抑えるための経皮的医薬製剤
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
BRPI0812000A2 (pt) * 2007-05-30 2014-11-18 Microdose Therapeutx Inc Métodos e composições para administração de oxibutinina
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
KR20130135239A (ko) 2010-08-03 2013-12-10 앨씨알엑스, 인크. 과민성 방광 치료를 위한 베타-3 아드레날린 수용체 작용제 및 무스카린 수용체 길항제의 약학적 배합제
TW201338772A (zh) 2012-02-09 2013-10-01 Altherx Inc 藥學組合物
JP2012176958A (ja) * 2012-04-20 2012-09-13 Watson Pharmaceuticals Inc （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
US20140135392A1 (en) * 2012-11-13 2014-05-15 NeuRx Pharmaceuticals LLC Methods for the treatment of sialorrhea
CN104116760A (zh) * 2014-07-14 2014-10-29 玉庆花 一种治疗遗尿的口服液
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
PT3365321T (pt) 2015-10-23 2024-01-12 B3Ar Therapeutics Inc Zwiterião de solabegron e suas utilizações

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL124473C (da) * 1960-07-26
BE902605A (fr) * 1985-06-06 1985-09-30 Therabel Res S A N V Composition pharmaceutique utilisable dans le traitement des maladies des voies urinaires, son procede de preparation et methode d'utilisation de cette composition.
PT100502A (pt) * 1991-05-20 1993-08-31 Alza Corp Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
JP3066515B2 (ja) * 1992-11-11 2000-07-17 久光製薬株式会社 尿失禁治療用経皮投与製剤
CA2167526A1 (en) * 1993-09-29 1995-04-06 Lina Tormen Taskovich Monoglyceride/lactate ester permeation enhancer

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039519A2 (es) * 2001-11-06 2003-05-15 Osmotica Corp. Forma de dosificación de liberación controlada dual
WO2003039436A2 (es) * 2001-11-06 2003-05-15 Osmotica Costa Rica Sociedad Anonima Composiciones farmaceuticas que contienen oxibutinina
WO2003039436A3 (es) * 2001-11-06 2004-02-26 Osmotica Costa Rica Sa Composiciones farmaceuticas que contienen oxibutinina
WO2003039519A3 (es) * 2001-11-06 2004-03-25 Osmotica Corp Forma de dosificación de liberación controlada dual

Also Published As

Publication number Publication date
SK103597A3 (en) 1999-03-12
WO1996023492A1 (en) 1996-08-08
PL321498A1 (en) 1997-12-08
CN1179714A (zh) 1998-04-22
AU706741B2 (en) 1999-06-24
FI973163A0 (fi) 1997-07-30
US5677346A (en) 1997-10-14
AU4966496A (en) 1996-08-21
GR3034974T3 (en) 2001-02-28
SK283313B6 (sk) 2003-05-02
HUP9800794A2 (hu) 1998-07-28
EP0806948A1 (en) 1997-11-19
FI973163A (fi) 1997-09-30
JPH11511730A (ja) 1999-10-12
PT806948E (pt) 2001-02-28
CA2211400C (en) 2007-01-23
CZ242197A3 (en) 1997-12-17
DE69610290T2 (de) 2001-03-29
NO973516L (no) 1997-08-07
PL182768B1 (pl) 2002-02-28
DE69610290D1 (de) 2000-10-19
NO973516D0 (no) 1997-07-30
EP0806948B1 (en) 2000-09-13
DK0806948T3 (da) 2000-12-18
HK1017986A1 (en) 1999-12-10
HUP9800794A3 (en) 1999-05-28
CZ290093B6 (cs) 2002-05-15
NZ303372A (en) 1999-01-28
MX9705820A (es) 1997-10-31
UA45387C2 (uk) 2002-04-15
CN1151786C (zh) 2004-06-02
RU2181589C2 (ru) 2002-04-27
BR9607001A (pt) 1997-10-28
ATE196252T1 (de) 2000-09-15
NO315927B1 (no) 2003-11-17
CA2211400A1 (en) 1996-08-08
KR100390271B1 (ko) 2003-10-04

Similar Documents

Publication Publication Date Title
ES2150663T3 (es) Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
CO4290353A1 (es) Agonistas de estrogeno
ES2148229T3 (es) Eteres y tioeteres en la posicion 17 de 4-aza-esteroides.
NO2012015I1 (no) Dapoxetine i en hver form beskyttet av basis patent nr 330562
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
AR042345A2 (es) Un procedimiento para la preparacion de una composicion farmaceutica para el tratamiento de aterosclerosis que contiene 8.9 - dehidroesterona o sus sales de la misma
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
ES2105525T3 (es) 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
MX9307332A (es) 3-(aminoalquilamino)-1,2-bencisoxasoles substituidos y compuestos relacionados.
GT199900015A (es) Procedimiento para tratar la insuficiencia cardiaca
PA8426801A1 (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
ES2053668T3 (es) Derivados de poliamina como agentes antineoplasicos.
ES2186153T3 (es) Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc.
ES2175153T3 (es) Uso de inhibidores de colinesterasa para la fabricacion de un medicamento para el tratamiento de la xerostomia.
AR005866A1 (es) Composicion farmaceutica antioxidante
MX9303422A (es) Benzodiazepinas, procedimiento para su preparacion y medicamento que las contiene.
KR920003972A (ko) 프로스타시클린 화합물을 이용한 백내장 치료
ES2192608T3 (es) Uso de derivados de alilamina tales como terbinafina, en la fabricacion de un medicamento para el tratamiento de la infeccion por helicobacter pylori de enfermedades asociadas.
ID26946A (id) Senyawa-senyawa baru
PA8480401A1 (es) Un metodo para la prevencion del inicio del asma

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 806948

Country of ref document: ES